{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T12:23:22Z","timestamp":1751718202594},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,6,1]]},"DOI":"10.1093\/jac\/dki142","type":"journal-article","created":{"date-parts":[[2005,5,11]],"date-time":"2005-05-11T02:03:47Z","timestamp":1115777027000},"page":"824-827","source":"Crossref","is-referenced-by-count":5,"title":["Role of viral kinetics under HCV therapy in HIV\/HCV-coinfected patients"],"prefix":"10.1093","volume":"55","author":[{"given":"Angel Luis","family":"Ballesteros","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Fuster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramon","family":"Planas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bonaventura","family":"Clotet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Tural","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2005,5,10]]},"reference":[{"key":"key\n\t\t\t\t20171010142540_R1","doi-asserted-by":"crossref","unstructured":"Manns MP, McHutchison JG, Gordon S et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet2001; 358: 958\u201365.","DOI":"10.1016\/S0140-6736(01)06102-5"},{"key":"key\n\t\t\t\t20171010142540_R2","doi-asserted-by":"crossref","unstructured":"Fried M, Shiffman M, Reddy R et al. Peg-interferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New Engl J Med2002; 347: 975\u201382.","DOI":"10.1056\/NEJMoa020047"},{"key":"key\n\t\t\t\t20171010142540_R3","doi-asserted-by":"crossref","unstructured":"Torriani FJ, Rodriguez-Torres M, Rockstroh JK et al. (APRICOT Study Group) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV patients. New Engl J Med2004; 351: 438\u201350.","DOI":"10.1056\/NEJMoa040842"},{"key":"key\n\t\t\t\t20171010142540_R4","unstructured":"Carrat F, Bani-Sadr F, Pol S et al. ANRS HC02-RIBAVIC study team. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA2004; 15: 292 (23), 2839\u201348."},{"key":"key\n\t\t\t\t20171010142540_R5","doi-asserted-by":"crossref","unstructured":"P\u00e9rez-Olmeda M, N\u00fa\u00f1ez M, Romero M et al. Pegylated IFN-\u03b12b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS2003; 17: 1023\u20138.","DOI":"10.1097\/00002030-200305020-00011"},{"key":"key\n\t\t\t\t20171010142540_R6","doi-asserted-by":"crossref","unstructured":"Neumann AU, Lam NP, Dahari H et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science1998; 282: 103\u20137.","DOI":"10.1126\/science.282.5386.103"},{"key":"key\n\t\t\t\t20171010142540_R7","doi-asserted-by":"crossref","unstructured":"Herrmann E, Lee J-H, Marinos G et al. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology2003; 37: 1351\u20138.","DOI":"10.1053\/jhep.2003.50218"},{"key":"key\n\t\t\t\t20171010142540_R8","doi-asserted-by":"crossref","unstructured":"Cribier B, Rey D, Schmitt C et al. High hepatitis C viraemia and impaired antibody response in patients coinfected with HIV. AIDS1995; 9: 1131\u20136.","DOI":"10.1097\/00002030-199510000-00003"},{"key":"key\n\t\t\t\t20171010142540_R9","doi-asserted-by":"crossref","unstructured":"Torriani FJ, Ribeiro RM, Gilbert TL et al. Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics during HCV treatment in HCV\/HIV coinfection. J Infect Dis2003; 188: 1498\u2013507.","DOI":"10.1086\/379255"},{"key":"key\n\t\t\t\t20171010142540_R10","doi-asserted-by":"crossref","unstructured":"Talal AH, Shata TM, Markatou M et al. Virus dynamics and immune responses during treatment in patients coinfected with hepatitis C and HIV. J Acquir Immune Defic Syndr2004; 35: 103\u201313.","DOI":"10.1097\/00126334-200402010-00001"},{"key":"key\n\t\t\t\t20171010142540_R11","doi-asserted-by":"crossref","unstructured":"Ballesteros AL, Franco S, Fuster D et al. Early HCV dynamics on Peg-interferon and ribavirin in HIV\/HCV co-infection: indications for the investigation of new treatment approaches. AIDS2004; 18: 59\u201366.","DOI":"10.1097\/00002030-200401020-00007"},{"key":"key\n\t\t\t\t20171010142540_R12","doi-asserted-by":"crossref","unstructured":"Barnes E, Harcourt G, Brown D et al. The dynamics of T-lymphocyte responses during combination therapy for chronic hepatitis C virus infection. Hepatology2002; 36: 743\u201354.","DOI":"10.1053\/jhep.2002.35344"},{"key":"key\n\t\t\t\t20171010142540_R13","doi-asserted-by":"crossref","unstructured":"Davis GL. Monitoring of viral levels during therapy of hepatitis C. Hepatology2002; 36: 5 Suppl 1, 145\u201351.","DOI":"10.1053\/jhep.2002.36798"},{"key":"key\n\t\t\t\t20171010142540_R14","doi-asserted-by":"crossref","unstructured":"Nguyen TT, Sedghi-Vaziri A, Wilkes LB et al. Fluctuations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infection. J Viral Hepat1996; 3: 75\u20138.","DOI":"10.1111\/j.1365-2893.1996.tb00084.x"},{"key":"key\n\t\t\t\t20171010142540_R15","doi-asserted-by":"crossref","unstructured":"Puoti M, Gargiulo F, Roldan EQ et al. Liver damage and kinetics of hepatitis C virus and human immunodeficiency virus replication during the early phases of combination of antiretroviral treatment. J Infect Dis2000; 181: 2033\u20136.","DOI":"10.1086\/315529"},{"key":"key\n\t\t\t\t20171010142540_R16","unstructured":"Tural C, G\u00f3mez G, Martinez MA et al. Impact of highly active antiretroviral therapy interruption strategies in plasma hepatitis C virus kinetics in human immunodeficiency and hepatitis C virus coinfected patients. In: Abstracts of the XV International AIDS Conference, Bangkok, Thailand, 2004. Abstract WeOrB1326. IAS International AIDS Society, Geneva, Switzerland."},{"key":"key\n\t\t\t\t20171010142540_R17","doi-asserted-by":"crossref","unstructured":"Cooper CL, Cameron DW. Review of the effect of highly active antiretroviral therapy on hepatitis C virus (HCV) RNA levels in human immunodeficiency virus and HCV coinfection. Clin Infect Dis2002; 35: 873\u20139.","DOI":"10.1086\/342388"},{"key":"key\n\t\t\t\t20171010142540_R18","doi-asserted-by":"crossref","unstructured":"Halfon P, Neumann AU, Bourliere M et al. Slow viral dynamics of hepatitis C virus genotype 4. J Viral Hepat2003; 10: 351\u20133.","DOI":"10.1046\/j.1365-2893.2003.00433.x"},{"key":"key\n\t\t\t\t20171010142540_R19","doi-asserted-by":"crossref","unstructured":"Lam NP, Neumann AU, Gretch DR et al. Dose-dependent acute clearance of hepatitic C genotype 1 virus with interferon alfa. Hepatology1997; 26: 226\u201331.","DOI":"10.1002\/hep.510260130"},{"key":"key\n\t\t\t\t20171010142540_R20","doi-asserted-by":"crossref","unstructured":"Jessner W, Gschwantler M, Steindl-Munda P et al. Primary interferon resistance and treatment response in chronic hepatitis C infection: a pilot study. Lancet2001; 358: 1241\u20132.","DOI":"10.1016\/S0140-6736(01)06356-5"},{"key":"key\n\t\t\t\t20171010142540_R21","doi-asserted-by":"crossref","unstructured":"Layden JE, Layden TJ, Reddy KR et al. First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline. J Viral Hepat2002; 9: 332\u20133.","DOI":"10.1046\/j.1365-2893.2002.00377.x"},{"key":"key\n\t\t\t\t20171010142540_R22","doi-asserted-by":"crossref","unstructured":"Ferenci P, Brunner H, Nachbaur K et al. Combination of interferon induction therapy and ribavirin in chronic hepatitis C. Hepatology2001; 34: 1006\u201311.","DOI":"10.1053\/jhep.2001.28706"},{"key":"key\n\t\t\t\t20171010142540_R23","doi-asserted-by":"crossref","unstructured":"Rockstroh JK, Mudar M, Lichterfeld M et al. Pilot study of interferon alpha high-dose induction therapy in combination with ribavirin for chronic hepatitis C in HIV-co-infected patients. AIDS2002; 16: 2083\u20135.","DOI":"10.1097\/00002030-200210180-00016"},{"key":"key\n\t\t\t\t20171010142540_R24","doi-asserted-by":"crossref","unstructured":"Zeuzem S, Welsch C, Herrmann E. Pharmacokinetics of peginterferons. Semin Liver Dis2003; 23 Suppl 1: 23\u20138.","DOI":"10.1055\/s-2003-41631"},{"key":"key\n\t\t\t\t20171010142540_R25","doi-asserted-by":"crossref","unstructured":"Formann E, Jessner W, Bennett L et al. Twice weekly administration of peginterferon \u03b12b improves viral kinetics in patients with chronic hepatitis C genotype 1. J Viral Hepat2003; 10: 271\u20136.","DOI":"10.1046\/j.1365-2893.2003.00446.x"},{"key":"key\n\t\t\t\t20171010142540_R26","doi-asserted-by":"crossref","unstructured":"Buti M, Vald\u00e9s A, S\u00e1nchez-\u00c1vila F et al. Extending combination therapy with peginterferon alfa-2b plus ribavirin for genotype 1 chronic hepatitis C late responders: report of 9 cases. Hepatology2003; 37: 1226\u20137.","DOI":"10.1053\/jhep.2003.50107"},{"key":"key\n\t\t\t\t20171010142540_R27","doi-asserted-by":"crossref","unstructured":"Barnes E, Harcourt G, Brown D et al. The dynamics of T-lymphocyte responses during combination therapy for chronic hepatitis C virus infection. Hepatology2002; 36: 743\u201354.","DOI":"10.1053\/jhep.2002.35344"},{"key":"key\n\t\t\t\t20171010142540_R28","doi-asserted-by":"crossref","unstructured":"Shiffman ML, Hofmann CM, Contos MJ et al. A randomized, controlled trial of maintenance interferon for treatment of chronic hepatitis C non-responders. Gastroenterology1999; 117: 1164\u201372.","DOI":"10.1016\/S0016-5085(99)70402-6"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/55\/6\/824\/2155787\/dki142.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T08:55:09Z","timestamp":1586249709000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/jac\/article\/55\/6\/824\/725619\/Role-of-viral-kinetics-under-HCV-therapy-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5,10]]},"references-count":28,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2005,5,10]]},"published-print":{"date-parts":[[2005,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dki142","relation":{},"ISSN":["1460-2091","0305-7453"],"issn-type":[{"value":"1460-2091","type":"electronic"},{"value":"0305-7453","type":"print"}],"subject":[],"published-other":{"date-parts":[[2005,6]]},"published":{"date-parts":[[2005,5,10]]}}}